Skip to main content
. 2018 Sep 20;18:81. doi: 10.1186/s12894-018-0393-9

Fig. 1.

Fig. 1

Proportion of patients receiving denosumab or zoledronic acid who developed hypocalcaemia of any grade. Figure reproduced with permission from Body et al. Eur J Cancer 2015;51:1812–21 under the Creative Commons licence (https://creativecommons.org/licenses/by-nc-nd/4.0/) [11]